Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxalobacter

Latest Information Update: 28 Dec 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Ixion Biotechnology
Developer OxThera
Class Bacteria; Probiotics
Mechanism of Action Bacteria replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Primary hyperoxaluria; Short bowel syndrome
New Molecular Entity No

Highest Development Phases

Phase III Primary hyperoxaluria
No development reported Short bowel syndrome

Most Recent Events

28 Dec 2018 OxThera AB plans a phase III trial for Primary hyperoxaluria in Germany (EudraCT2018-003576-12)
15 Nov 2018 OxThera has patent protection for Oxalobacter formigenes secretagogues in USA
11 Jul 2018 Phase-III clinical trials in Primary hyperoxaluria (In adolescents, In children, In the elderly, In adults) in United Kingdom and USA (PO)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight